Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

Allergic Rhinitis Clinical Trial

Official title:

Study on the Efficacy and Safety of Bencycloquidium Bromide Nasal Spray Alone or in Combination With Mometasone Furoate Aqueous Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05038202
• Other study ID #: YG-BLT-PMS001
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: June 16, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: March 2024
• Source: Yingu Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatments. Group A：Subjects with Bencycloquidium Bromide Nasal Spray, Group B：Subjects with Mometasone Furoate Aqueous Nasal Spray, Group C：Subjects with Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray.The main purpose of the trial is to evaluate the efficacy of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.

Description:

The Secondary purpose is to evaluate the effectiveness of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis with nasal itching, nasal congestion, and sneezing. And evaluate the safety of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 450
• Est. completion date: June 30, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The diagnosis of allergic rhinitis meets the standards of "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis" (2015, Tianjin);
• The previous or current symptom onset is =4d/week and =4 consecutive weeks; the symptoms are severe or serious (Total Nasal Symptom Scores=6 points) with single symptom score of runny nose =2 points;
• Able to complete the symptom score as required;
• Subjects voluntarily participate in this study, and sign a written informed consent form. Use study drugs, complete evaluation and follow-up in accordance with the requirements of this study.

Exclusion Criteria:

• Those who are known to be allergic to the ingredients contained in test drugs.
• Used vasoconstrictors within 1 day; used topical or oral antihistamines within 3 days; used topical glucocorticoids and leukotriene receptor antagonists within 7 days; used oral glucocorticoid drugs within 30 days.
• Those who have been diagnosed as asthma or have asthma symptoms (wheezing, shortness of breath, chest tightness, coughing).
• Patients suffering from respiratory infections or abnormal nasal anatomy (such as nasal polyps, nasal septum deviation, etc.) one month before enrollment.
• Received immunotherapy and nasal surgery Within 6 months before enrollment.
• Patients with dry eye.
• Patients with glaucoma.
• Patients with enlarged prostate who have difficulty urinating.
• People with mental disorders or impaired consciousness.
• Pregnancy (patients report pregnancy), those who have a pregnancy plan within 6 months, and lactating women.
• Patients considered by the researcher to be unsuitable to participate in this study.

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

Intervention

Drug:
• Bencycloquidium Bromide Nasal Spray
The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist. This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis.
• Mometasone Furoate Aqueous Nasal Spray
Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension. This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment.

Locations

Country	Name	City	State
China	Beijing friendship hospital, CMU	Beijing	Beijing
China	Beijing Shijitan Hospital,CMU	Beijing	Beijing
China	Beijing Tongren Hospital,CMU	Beijing	Beijing
China	The third affliation hospital of Sun YAT-SEN university	Guangzhou	Guangdong
China	Jiangsu Province hospital	Nanjing	Jiangsu
China	Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Yingu Pharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events	adverse clinical events that occur during drug treatment, which may not have a causal relationship with the drug.	From the start of the enrollment to the end of the study, an average of 35days
Primary	Symptom scores of runny nose	It is the symptom scores of runny nose, based on a 4-point method: 0 points: asymptomatic; point: mild symptoms (symptoms are mild and easy to tolerate); points: moderate symptoms (significant symptoms, annoying, but tolerable); points: Severe symptoms (symptoms cannot be tolerated, affecting daily life and/or sleep).	immediately after the final intervention
Secondary	Visual Analogue Scale score of runny nose,nasal congestion, nasal itching, and sneezing	Visual Analysis Scale (VAS, Visual Analysis Scale) score, from 0 to 10 points, the total symptoms of nasal congestion, nasal itching, and sneezing gradually increase; 0 of which is asymptomatic; 3 and below 3-the symptoms are mild and can be tolerated; 4 to 6 - the symptoms are severe but tolerable; 7 to 10 -symptoms are severe and unbearable, which affect appetite and sleep. The subjects calibrate it according to the intensity of the symptoms	immediately after the final intervention
Secondary	Visual Analogue Scale score of total nasal symptoms	24-hour retrospective review of the average change in the Visual Analogue Scale score of total nasal symptoms compared to the baseline. From 0 to 10 points, 0 of which is asymptomatic; 3 and below 3-the symptoms are mild and can be tolerated; 4 to 6 - the symptoms are severe but tolerable; 7 to 10 -symptoms are severe and unbearable, which affect appetite and sleep. The subjects calibrate it according to the intensity of the symptoms	immediately after the final intervention
Secondary	Total Nasal Symptom Scores and Drug score	Total nose symptom TNSS(Total Nasal Symptom Scores): It is the sum of 4 individual symptom scores of runny nose, nasal congestion, nasal itching and sneezing, totaling 12 points, and each symptom score is based on a 4-point method: 0 points: asymptomatic; point: mild symptoms (symptoms are mild and easy to tolerate); points: moderate symptoms (significant symptoms, annoying, but tolerable); points: Severe symptoms (symptoms cannot be tolerated, affecting daily life and/or sleep).; Drug score: 0 points: No other drugs used to treat Allergic Rhinitis; point: Use oral antihistamines (Loratadine tablets designated in the trial, trade name: Claritin); points: use nasal hormones (not applicable for this trial); points: use oral hormones (not applicable for this trial).	immediately after the final intervention
Secondary	The questionnaire of patient with global impression of change	the subject's overall impression of symptoms change. From 0 to 4: 0 points: not evaluated; point: the symptoms are completely controlled or disappeared; points: Significant improvement in symptoms; points: the improvement of symptoms is not obvious; points: Symptoms are not improved or even worsened.	immediately after the final intervention
Secondary	The questionnaire of Rhinoconjunctivitis Quality of Life	the quality of sleep, symptoms of eyes, feelings of emotions due to the influence of nasal symptoms. From 0-6: 0-1 points: almost asymptomatic; 2-3 point: mild symptoms (symptoms are mild and easy to tolerate); 4-5 points: moderate symptoms (significant symptoms, annoying, but tolerable); 6 points: Severe symptoms	immediately after the final intervention